Company Description
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue.
Our proprietary Capture and Contain ™, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity.
We are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs.
We refer to our additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients as Trap and Target ™ Our nasal hydrogels have been designed to serve as a non-invasive and fast-acting system.
The hydrogels are formulated as an innovative mixture of mucoadhesive polymers (e.g., sodium alginate) which are Generally Recognized as Safe, or GRAS, by the Federal Drug Administration.
Our mucoadhesive polymers derived from seaweed polysaccharides possess promising features as they are renewable, biodegradable, biocompatible, and environment friendly.
C&C product candidates are not expected to be considered as drugs by the FDA but as medical devices.
| Country | Israel |
| Founded | 2005 |
| Industry | Health Care |
| Sector | Biotechnology |
| Employees | 3 |
| CEO | Tomer Izraeli |
Contact Details
Address: 5 Ha-Tidhar Street Raanana, 4366507 Israel | |
| Phone | +972-9-93740333 |
| Website | polyrizon-biotech.com |
Stock Details
| Ticker Symbol | PLRZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001893645 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Tomer Izraeli | Chief Executive Officer, Director |
| Nir Ben Yosef | Chief Financial Officer |
| Dr. Eyal S. Ron | Chief Technology Officer |
| Dr. Tidhar Turgeman | Chief R&D Officer |
| Daphna Avital | Chief People Officer |
| Dr. Roy Borochov | Director |
| Liron Carmel | Director |
| Oz Adler | Director |
| Raul Srugo | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | RW WD | Filing |
| Mar 28, 2024 | RW | Filing |
| Feb 3, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jan 10, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Dec 19, 2022 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Oct 7, 2022 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Aug 10, 2022 | F-1 | Registration statement for certain foreign private issuers |
| May 27, 2022 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 4, 2022 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Apr 14, 2022 | DRS/A | [Amend] [Cover] Draft Registration Statement |